MDPI and ACS Style
Patzke, C.L.; Duffy, A.P.; Duong, V.H.; El Chaer, F.; Trovato, J.A.; Baer, M.R.; Bentzen, S.M.; Emadi, A.
Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia. J. Clin. Med. 2020, 9, 536.
https://doi.org/10.3390/jcm9020536
AMA Style
Patzke CL, Duffy AP, Duong VH, El Chaer F, Trovato JA, Baer MR, Bentzen SM, Emadi A.
Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia. Journal of Clinical Medicine. 2020; 9(2):536.
https://doi.org/10.3390/jcm9020536
Chicago/Turabian Style
Patzke, Ciera L., Alison P. Duffy, Vu H. Duong, Firas El Chaer, James A. Trovato, Maria R. Baer, Søren M. Bentzen, and Ashkan Emadi.
2020. "Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia" Journal of Clinical Medicine 9, no. 2: 536.
https://doi.org/10.3390/jcm9020536